Document Detail

Anticoagulation variability between centres: implications for comparative prosthetic valve assessment.
MedLine Citation:
PMID:  3272209     Owner:  NLM     Status:  MEDLINE    
One of the major determinants in the choice of a mechanical prosthetic valve is that valve's thromboembolic record but the thromboembolic (TE) rates may be substantially influenced by the levels of anticoagulation achieved. A detailed study of anticoagulation variability was undertaken in 834 patients who received one or more of a particular prosthesis (Medtronic-Hall) in one centre during a 7-year period from 1979 to 1987, but who attended 27 different anticoagulant clinics spread over a wide area. In addition, a questionnaire was sent to all 89 practising cardiac surgeons in the UK asking for their preferred range of International Normalised Ratio (INR) for patients with mechanical prosthetic valves. Both the local study (with 16,866 INR observations) and the national questionnaire (with a 53% response) revealed an enormous amount of variability. Median INR values (semi-interquartile range) varied from 2.2 to 3.9 (0.8-2.5) according to the anticoagulant clinic attended. The range of INR preferred by UK cardiac surgeons, but presumably not necessarily achieved, varied from 1.8-2.2 to 3.0-4.8, with 64% of surgeons preferring an INR less than 3.0. In comparison, standard US practice is to maintain prothrombin times equivalent to INR values of 4.0-5.0. Unless anticoagulant practice can be standardised internationally, comparison of TE complications between centres is meaningless, and casts doubt on the validity of TE rates quoted for particular prostheses, unless accompanied by a detailed analysis of anticoagulant control.
E G Butchart; P A Lewis; E N Kulatilake; I M Breckenridge
Related Documents :
10915479 - The emergency use of recombinant hirudin in cardiopulmonary bypass.
16724969 - Percutaneous left and right heart catheterization in fully anticoagulated patients util...
10514209 - Systematic review of randomized controlled trials of aspirin and oral anticoagulants in...
12508189 - Coronary angiography in the fully anticoagulated patient: the transradial route is succ...
17574129 - 3d and 2d delayed-enhancement magnetic resonance imaging for detection of myocardial in...
17123649 - Large recesses associated with left ventricular noncompaction: an unusual presentation ...
8542899 - Quantitation of myocardial iodine-123 mibg uptake in spet studies: a new approach using...
1417299 - Simplified correction of outflow obstruction after mitral valve replacement.
9533999 - Seeing objects smaller than they are: micropsia following right temporo-parietal infarc...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery     Volume:  2     ISSN:  1010-7940     ISO Abbreviation:  Eur J Cardiothorac Surg     Publication Date:  1988  
Date Detail:
Created Date:  1990-04-11     Completed Date:  1990-04-11     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8804069     Medline TA:  Eur J Cardiothorac Surg     Country:  GERMANY, WEST    
Other Details:
Languages:  eng     Pagination:  72-81     Citation Subset:  IM    
Department of Cardiac Surgery, University Hospital of Wales, Cardiff, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticoagulants / administration & dosage*
Aortic Valve
Heart Diseases / epidemiology,  etiology
Heart Valve Prosthesis / adverse effects*,  mortality
International Cooperation
Middle Aged
Mitral Valve
Outcome and Process Assessment (Health Care)
Prospective Studies
Prothrombin Time
Retrospective Studies
Risk Factors
Survival Rate
Thrombosis / epidemiology,  etiology
Tricuspid Valve
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Clinical application and patient selection in the use of a total artificial heart as a bridge for tr...
Next Document:  Pneumonectomy for severe inflammatory lung disease. Results in 64 consecutive cases.